Medication Competition Act

[Congressional Bills 119th Congress] [From the U.S. Government Publishing Office] [S. 4332 Introduced in Senate (IS)] <DOC> 119th CONGRESS 2d Session S. 4332 To require the Secretary of Health and Human Services to make determinations of the exclusivity periods for which licensed biological products are eligible. _______________________________________________________________________ IN THE SENATE OF THE UNITED STATES April 16 (legislative day, April 14), 2026 Ms. Hassan (for herself and Mr. Budd) introduced the following bill; which was read twice and referred to the Committee on Health, Education, Labor, and Pensions _______________________________________________________________________ A BILL To require the Secretary of Health and Human Services to make determinations of the exclusivity periods for which licensed biological products are eligible. Be it enacted by the Senate and House of Representatives of the United States of America in Congress assembled, SECTION 1. SHORT TITLE. This Act may be cited as the ``Medication Competition Act''. SEC. 2. DETERMINATION OF REFERENCE PRODUCT EXCLUSIVITY. Section 351(k)(9)(A)(iv) of the Public Health Service Act (42 U.S.C. 262(k)(9)(A)(iv)) is amended-- (1) by inserting ``determine any applicable exclusivity period under paragraph (6) or (7), and shall'' after ``the Secretary shall''; (2) by striking the period at the end and inserting ``, as follows:''; and (3) by adding at the end the following: ``(I) Exclusivity for first interchangeable biological products.-- ``(aa) Products licensed on or after the date of enactment.--With respect to a biological product licensed under this subsection on or after the date of enactment of the Medication Competition Act, the Secretary shall include on the list published under this subparagraph any applicable exclusivity period under paragraph (6), not later than 30 days after the earliest date on which an expiration date of such an exclusivity period can be known pursuant to paragraph (